MENU
CLOSE
Every tissue in the human body depends on a structural scaffold, also known as the extracellular matrix, or ECM. The cells need a place to anchor, organize and support normal tissue function, but the body loses this ability when the structure is lost or damaged.
This is the gap Conexeu is working to address. Our CXU™ medical device candidate is a collagen-based ECM scaffold designed to provide a temporary structural framework that supports tissue regeneration.
Our CXU scaffold is designed to provide a temporary structural environment that may support host tissue integration and remodeling, to enable multi-cell migration and proliferation from the surrounding local tissue into the ECM scaffold.
Supports the development of native tissue architecture over time, may support creating the conditions for organized, adaptive restoration consistent with tissue regeneration.
Designed to support the formation of tissue that may closely reflect native structure and function, beyond just repair.
One Foundation. Across Many Conditions.
The ECM serves as the body’s structural and functional support. When that structure is degraded or damaged through trauma, aging or disease, the tissue’s ability to repair or regenerate is reduced. This is the gap Conexeu is designed to address.
One platform, one formula, one device for broad potential use across a range of human and animal applications.
.png)
.avif)
30-year global healthcare leader developing and building category-defining brands. Current board member of Castle Biosciences (CSTL), a precision diagnostics company.
8-Figure Exit, Novaestiq Corp. Co-Founder & CEO, built the ‘next-generation’ aesthetics platform, raised $10M+ pre-Series A, and FDA approved in Sept ’25.
Member of Galderma’s Executive Leadership Team that crafted the $10.2B sale from Nestle to the EQT Group.
5 years as Galderma’s North American President & GM, scaling Aesthetics, Consumer, and Prescription businesses by 50%+ to $2.1B+ across Dysport®, Sculptra®, Restylane®, Cetaphil®, Differin®, Proactiv® and Epiduo®.
Attained the 1st FDA-approved RX-to-OTC acne switch in 30 years.
SVP and VP for Novartis across multiple verticals-Pharma, Oncology, Nutrition and Consumer.
M.D. Faculty of Medicine,Universidad Nacional Autónoma de México (UNAM), Mexico City.
Ph.D. (Experimental Medicine) Department of Surgery, Plastic and Re-constructive Surgery, UBC.
6 translational tissue-engineering programs (in-vivo bioreactor, liquid skins ubstitute, 3-D bladder/kidney tumor platforms.
10+ pre-clinical / animal studies advancing regenerative surgery toward clinic.
40+ Published peer-reviewed clinical and research papers (plastic surgery, wound healing, stem-cell therapy, 3-D bio-printing)
1 U.S. patent (+ licensed IP) for an implantable modular bio-reactor sold to the U.S. Army
8 Industry & academic collaborations in regenerative medicine.
25+ years in dermatology and aesthetics, he served as CMO of Suneva Medical (acquired by Tiger Bio, 2024) and VP of Medical Affairs for Merz North America, leading the launch of Radiesse.
8 FDA-related post-market / label-expansion programs (Radiesse®, Xeomin®, Belotero®, Instalift®, HD-PRP, etc.)
15 clinical programs in regenerative aesthetics, fillers and thread-lifts.
20+ Published Research Papers (PMMA collagen filler science, wound biology).
25 patents (3 direct-inventor; 22 co-inventor) on aromatic-aldehyde dermatologic therapeutics & ECM biology.
10 Affiliated Aesthetic / Pharma Companies (Merz, Suneva, Endo, Sinclair, Servier, Roche, Cytrellis, Camurus, Paradigm, Premier HC).
Financial executive with nearly 40 years in accounting and tax management.
Co-founded a Canadian biotech developing bio-pharmaceutical products. Deep expertise in small-cap markets, securities regulations, and corporate governance.
Managed audits for multiple go-public transactions, supporting capital raises and growth initiatives.
25 year entrepreneur and capital markets professional with experience leading a Canadian biotech from startup to IPO, raising $30M in 9 months.
Founder of Conexeu Sciences; led the acquisition of the Conexeu’s global core collagen/ECM IP on an outright basis. (no licensing fees or royalty obligations)
Raised and advised on more than $8M in Conexeu seed capital, coordinating early-stage financings and investor syndicates.
Assembled Conexeu’s world-class management and advisory team across regenerative medicine, aesthetics, wound care, and capital markets.
20+ years of experience in operational excellence, brand development, M&A integration, finance, and commercial growth. Experience includes roles across Fortune 500 and global healthcare organizations. Held multiple positions at Galderma spanning Marketing, Finance, Project Management, Launch Excellence, and Commercial Strategy.
Earlier career included leadership roles in audit, finance, integration, and operations across financial services and investment banking.
Recognized by Fort Worth CEO Magazine as a Top 20 Woman to Watch in Business.
25+ years in finance, transformation, and corporate development, supporting CEOs, boards, and private equity sponsors.
Transaction experience spans across M&A, licensing, carve-outs, IPO readiness, restructurings, and exits.
Founder of Allyght Advisory, serving private equity-backed and privately held companies including structuring strategic partnerships and advising executive teams on growth and transaction execution.
Former Vice President of Corporate Development and Head of Transactions at Galderma, with responsibility for acquisitions, divestitures, licensing agreements, and IPO readiness.
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source.Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32.The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.
